Published in the Guttmacher Policy Review in the summer of 2015, this article makes the case for greater investment in the development of multipurpose prevention technologies (MPTs) that would provide protection against multiple health risks, such as unintended pregnancy, HIV, and sexually transmitted infections. No large pharmaceutical company has a significant program in MPT research, so the development of these promising products depends on support from governments and foundations.